kitepharma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: /sitecore Disallow: /Sitecore Disallow: /sitecore_files/ Disallow: /sitecore modules/ Disallow: /App_Browsers/ Disallow: /App_config/ Disallow: /App_Data/ Disallow: /temp/ Disallow: /upload/ Disallow: /xsl/ Disallow: /404* Disallow: /500* Sitemap: | ||
Meta Tags
| Title | Kite Pharma, Changing the Way Cancer is |
| Description | Focused on the Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 40.70.27.35 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
kitepharma.com Valuation
|
US$163,828,484
Last updated: 2023-05-01 06:36:34
kitepharma.com has Semrush global rank of 64,606. kitepharma.com has an estimated worth of US$ 163,828,484, based on its estimated Ads revenue. kitepharma.com receives approximately 18,903,287 unique visitors each day. Its web server is located in United States, with IP address 40.70.27.35. According to SiteAdvisor, kitepharma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$163,828,484 |
| Daily Ads Revenue | US$151,227 |
| Monthly Ads Revenue | US$4,536,789 |
| Yearly Ads Revenue | US$54,441,466 |
| Daily Unique Visitors | 1,260,220 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| kitepharma.com. | A | 3599 | IP: 40.70.27.35 |
| kitepharma.com. | NS | 3600 | NS Record: dns2.cscdns.net. |
| kitepharma.com. | NS | 3600 | NS Record: dns1.cscdns.net. |
| kitepharma.com. | MX | 600 | MX Record: 10 mxb-002ff601.gslb.pphosted.com. |
| kitepharma.com. | MX | 600 | MX Record: 5 ppa. |
| kitepharma.com. | MX | 600 | MX Record: 5 ppb. |
| kitepharma.com. | MX | 600 | MX Record: 10 mxa-002ff601.gslb.pphosted.com. |
| kitepharma.com. | TXT | 3599 | TXT Record: CFVERIFY346790 |
| kitepharma.com. | TXT | 599 | TXT Record: MS=ms39432607 |
| kitepharma.com. | TXT | 599 | TXT Record: MS=ms80836664 |
| kitepharma.com. | TXT | 3599 | TXT Record: Zoom_Verify_pA2pQbR-x!PhCGgO |
| kitepharma.com. | TXT | 3599 | TXT Record: adobe-idp-site-verification=adb0a46c-6384-465a-a098-6203733b378e |
| kitepharma.com. | TXT | 3599 | TXT Record: apple-domain-verification=Z8iIDlzVzz3ePH3F |
| kitepharma.com. | TXT | 3599 | TXT Record: cwsauthsprod-wr.azurewebsites.net |
| kitepharma.com. | TXT | 3599 | TXT Record: docusign=1554ba3e-716d-4206-aa53-62b7bec37aa4 |
| kitepharma.com. | TXT | 3599 | TXT Record: docusign=6059c332-6aec-49ef-9ef7-5702ad166c1c |
| kitepharma.com. | TXT | 3599 | TXT Record: v=spf1 include:spf.protection.outlook.com include:spf-002ff601.pphosted.com -all |
HtmlToTextCheckTime:2023-05-01 06:36:34
| Find a Treatment Center Investor Relations Contact Us KiteKonnect® About Us Our Mission Our Story Therapeutic Areas Leadership Kite Locations Science & Medicine Our Technology Our Therapies Pipeline Trials & Expanded Access External Research Program (ERP) Newsroom Newsroom Press Releases Company Statements Media Kit Careers Now Hiring Careers at Kite Manufacturing Careers at Kite Early Talent Programs at Kite Culture & Benefits Utility Contact Us KiteKonnect® BACK TO MAIN MENU Company Statements Kite’s Yescarta® First CAR T-cell Therapy to Receive Health Canada Authorization for Use as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma Christi Shaw to Depart Gilead and Kite Leadership End of Q1 Kite’s Yescarta® is First Car T-Cell Therapy Recommended for Routine Use in England, United Kingdom Kite Expands Cell Therapy Manufacturing Operations in Maryland Supreme Court Denied Juno’s Appeal Request in Juno vs. Kite Case Kite Receives U.S. Food and Drug Administration (FDA) |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 0 Content-Type: text/html; charset=UTF-8 Location: https://kitepharma.com/ Date: Sat, 23 Oct 2021 22:03:37 GMT HTTP/2 301 content-length: 0 location: https://www.kitepharma.com/ server: Microsoft-IIS/10.0 x-powered-by: ASP.NET set-cookie: ARRAffinity=2a0213747367f547396a4721b13d6c25d0acae2549c20334b974732aa55ca086;Path=/;HttpOnly;Secure;Domain=kitepharma.com set-cookie: ARRAffinitySameSite=2a0213747367f547396a4721b13d6c25d0acae2549c20334b974732aa55ca086;Path=/;HttpOnly;SameSite=None;Secure;Domain=kitepharma.com date: Sat, 23 Oct 2021 22:03:37 GMT HTTP/2 200 date: Sat, 23 Oct 2021 22:03:38 GMT content-type: text/html; charset=utf-8 cache-control: no-cache, no-store pragma: no-cache expires: -1 vary: Accept-Encoding set-cookie: ASP.NET_SessionId=lu4gfi3sdvuexrqec2tdzmcd; path=/; HttpOnly; SameSite=Lax set-cookie: ASP.NET_SessionId=lu4gfi3sdvuexrqec2tdzmcd; path=/; HttpOnly; SameSite=Lax set-cookie: SC_ANALYTICS_GLOBAL_COOKIE=20f481ab46ba43da837834294de5a472|False; expires=Tue, 21-Oct-2031 22:03:38 GMT; path=/; HttpOnly set-cookie: __RequestVerificationToken=YGK57WgAlDTD73n3nBKvBcoWGnCE3XH2MqICTIYEofgzEYbzhMXaVkUiolRHoLVrZVptzD2sgIvKU0tbIcMj3-qb0381; path=/; HttpOnly x-frame-options: SAMEORIGIN x-frame-options: SAMEORIGIN request-context: appId=cid-v1:6768aa3e-6953-4f80-a634-cb45ec14a25d cf-cache-status: DYNAMIC expect-ct: max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct" server: cloudflare cf-ray: 6a2e41aace6d4945-STL |
kitepharma.com Whois Information
Domain Name: KITEPHARMA.COM Registry Domain ID: 1558919092_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2020-12-30T01:26:22Z Creation Date: 2009-06-11T22:53:46Z Registry Expiry Date: 2022-06-11T22:53:46Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: serverDeleteProhibited https://icann.org/epp#serverDeleteProhibited Domain Status: serverTransferProhibited https://icann.org/epp#serverTransferProhibited Domain Status: serverUpdateProhibited https://icann.org/epp#serverUpdateProhibited Name Server: DNS1.CSCDNS.NET Name Server: DNS2.CSCDNS.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-12T07:21:15Z <<< |